Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

     

News

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report and Accounts

🕔2/23/2017 9:20:20 AM 572

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives Second Payment for Detach Under The Agreement with Zoetis (NYSE:ZTS)

🕔1/30/2017 10:20:19 AM 1361

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. (NYSE:ZTS) for Detach(TM), Anatara's non-antibiotic anti-infective product.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Research Report 'A Good Gut Feeling' by NDF Research

🕔1/25/2017 10:24:29 AM 1118

NDF Research yesterday released its initiation report on Anatara Lifesciences Ltd (ASX:ANR). The report provided a valuation at $2.22 per share base case and $5.94 per share optimistic case using a DCF approach, with a target price of $4.00 per share sitting midpoint of their valuation range.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Update

🕔11/22/2016 8:27:13 AM 1162

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its updated investor presentation.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) AGM Presentation

🕔11/15/2016 11:51:40 AM 1225

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's AGM Presentation held on 15 November 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Chairman's Address to Shareholders

🕔11/15/2016 11:50:40 AM 1365

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the company's latest Chairman's Address to Shareholders at 2016 AGM.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Annual Report to Shareholders

🕔10/14/2016 11:17:04 AM 1533

Anatara Lifesciences Ltd (ASX:ANR) directors present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the year ended 30 June 2016.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Receives R&D Tax Refund

🕔10/14/2016 8:30:42 AM 1264

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received $420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔10/13/2016 8:25:28 AM 1242

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Read Full Article

Anatara Lifesciences Limited's (ASX:ANR) Antibiotic Alternative Edges Closer to Commercialisation as UN Declares Drug Resistance 'The Greatest and Most Urgent global risk'

🕔10/4/2016 8:30:00 AM 1467

Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).

Read Full Article
###

4,548 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 166) (Last 30 Days: 461) (Since Published: 4548) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Social Media